{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:14:05Z","timestamp":1790792045021,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Severe eosinophilic asthma (SEA) is characterised by elevated blood\/sputum eosinophil counts and airway inflammation, which can lead to mucus plug-mediated airway obstruction, increased exacerbation frequency, declines in lung function, and death. Benralizumab targets the alpha-subunit of the interleukin-5 receptor found on eosinophils, leading to rapid and near complete eosinophil depletion. This is expected to result in reduced eosinophilic inflammation, reduced mucus plugging and improved airway patency and airflow distribution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>BURAN is an interventional, single-arm, open-label, uncontrolled, prospective, multicentre study during which participants will receive three 30\u00a0mg subcutaneous doses of benralizumab at 4-week intervals. This study will use functional respiratory imaging (FRI), a novel, quantitative method of assessing patients\u2019 lung structure and function based on detailed, three-dimensional models of the airways, with direct comparison of images taken at Weeks 0 and 13. Patients aged\u2009\u2265\u200918\u00a0years with established SEA who may be receiving oral corticosteroids and\/or other asthma controller medications, who are inadequately controlled on inhaled corticosteroid-long-acting \u03b2<jats:sub>2<\/jats:sub>-agonist therapies and who have had\u2009\u2265\u20092 asthma exacerbations in the previous 12\u00a0months will be included. The objectives of BURAN are to describe changes in airway geometry and dynamics, measured by specific image-based airway volume and other FRI endpoints, following benralizumab therapy. Outcomes will be evaluated using descriptive statistics. Changes in FRI parameters, mucus plugging scores and central\/peripheral ratio will be quantified as mean percent change from baseline (Week 0) to Week 13 (\u00b1\u20095\u00a0days) and statistical significance will be evaluated using paired t-tests. Relationships between FRI parameters\/mucus plugging scores and conventional lung function measurements at baseline will be assessed with linear regression analyses for associations between outcomes, scatterplots to visualise the relationship, and correlation coefficients (Spearman\u2019s rank and Pearson\u2019s) to quantify the strength of these associations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The BURAN study will represent one of the first applications of FRI\u2014a novel, non-invasive, highly sensitive method of assessing lung structure, function and health\u2014in the field of biologic respiratory therapies. Findings from this study will increase understanding of cellular-level eosinophil depletion mechanisms and improvements in lung function and asthma control following benralizumab treatment.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> EudraCT: 2022-000152-11 and NCT05552508<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-023-02415-4","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T02:01:33Z","timestamp":1683079293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach"],"prefix":"10.1186","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct05552508","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eduardo","family":"Genofre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Carstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"DeBacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Muchmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Reynold A.","family":"Panettieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian H.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Trudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"2415_CR1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1471-2458-12-204","volume":"12","author":"T To","year":"2012","unstructured":"To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet L-P. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204.","journal-title":"BMC Public Health"},{"key":"2415_CR2","unstructured":"GINA. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA); 2022."},{"key":"2415_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/cea.12345","volume":"44","author":"X-Y Zhang","year":"2014","unstructured":"Zhang X-Y, Simpson JL, Powell H, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy. 2014;44:1137\u201345.","journal-title":"Clin Exp Allergy"},{"key":"2415_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40264-020-00926-3","volume":"43","author":"DJ Jackson","year":"2020","unstructured":"Jackson DJ, Korn S, Mathur SK, Barker P, Meka VG, Martin UJ, Zangrilli JG. Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab. Drug Saf. 2020;43:409\u201325.","journal-title":"Drug Saf"},{"key":"2415_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18176\/jiaci.0385","volume":"29","author":"I D\u00e1vila Gonz\u00e1lez","year":"2019","unstructured":"D\u00e1vila Gonz\u00e1lez I, Moreno Ben\u00edtez F, Quirce S. Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol. 2019;29:84\u201393.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2415_CR6","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","volume":"323","author":"J Bousquet","year":"1990","unstructured":"Bousquet J, Chanez P, Lacoste JY, Barn\u00e9on G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033\u20139.","journal-title":"N Engl J Med"},{"key":"2415_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","volume":"157","author":"E Wang","year":"2020","unstructured":"Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, Busby J, Jackson DJ, Pfeffer PE, Rhee CK, et al. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020;157:790\u2013804.","journal-title":"Chest"},{"key":"2415_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","volume":"160","author":"LG Heaney","year":"2021","unstructured":"Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, Christoff GC, Cosio BG, FitzGerald JM, Heffler E, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160:814\u201330.","journal-title":"Chest"},{"key":"2415_CR9","doi-asserted-by":"crossref","unstructured":"Perez-de-Lano L, Tran TN, Al-ahmad M, Alacqua M, Bulathsinhala L, Busby J, Canonica GW, Carter V, Chaudhry I, Christoff GC, et al. Characterization of Eosinophilic and Non-Eosinophilic Severe Asthma Phenotypes and Proportion of Patients with These Phenotypes in the International Severe Asthma Registry (ISAR). In C21 ADVANCES IN ADULT AND PEDIATRIC ASTHMA PHENOTYPING AND ENDOTYPING. 2020: A4525\u2013A4525.","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A4525"},{"key":"2415_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI95693","volume":"128","author":"EM Dunican","year":"2018","unstructured":"Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, Raymond WW, Lachowicz-Scroggins ME, Di Maio S, Hoffman EA, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128:997\u20131009.","journal-title":"J Clin Invest"},{"key":"2415_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11882-019-0868-0","volume":"19","author":"S Ueki","year":"2019","unstructured":"Ueki S, Miyabe Y, Yamamoto Y, Fukuchi M, Hirokawa M, Spencer LA, Weller PF. Charcot-Leyden crystals in eosinophilic inflammation: active cytolysis leads to crystal formation. Curr Allergy Asthma Rep. 2019;19:35\u201335.","journal-title":"Curr Allergy Asthma Rep"},{"key":"2415_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.anai.2022.02.021","volume":"129","author":"J Oppenheimer","year":"2022","unstructured":"Oppenheimer J, Hoyte FCL, Phipatanakul W, Silver J, Howarth P, Lugogo NL. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol. 2022;129:169.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2415_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1164\/rccm.200807-1056OC","volume":"180","author":"AL Innes","year":"2009","unstructured":"Innes AL, Carrington SD, Thornton DJ, Kirkham S, Rousseau K, Dougherty RH, Raymond WW, Caughey GH, Muller SJ, Fahy JV. Ex Vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am J Respir Crit Care Med. 2009;180:203\u201310.","journal-title":"Am J Respir Crit Care Med"},{"key":"2415_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy JV. Type 2 inflammation in asthma\u2014present in most, absent in many. Nat Rev Immunol. 2015;15:57\u201365.","journal-title":"Nat Rev Immunol"},{"key":"2415_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229238","volume":"15","author":"Y Yoshida","year":"2020","unstructured":"Yoshida Y, Takaku Y, Nakamoto Y, Takayanagi N, Yanagisawa T, Takizawa H, Kurashima K. Changes in airway diameter and mucus plugs in patients with asthma exacerbation. PLoS ONE. 2020;15: e0229238.","journal-title":"PLoS ONE"},{"key":"2415_CR16","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.chest.2022.03.003","volume":"162","author":"MJ McIntosh","year":"2022","unstructured":"McIntosh MJ, Kooner HK, Eddy RL, Jeimy S, Licskai C, Mackenzie CA, Svenningsen S, Nair P, Yamashita C, Parraga G. Asthma control, airway mucus, and 129Xe MRI ventilation after a single benralizumab dose. Chest. 2022;162:520.","journal-title":"Chest"},{"key":"2415_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/jcp.13.1.27","volume":"13","author":"MS Dunnill","year":"1960","unstructured":"Dunnill MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol. 1960;13:27\u201333.","journal-title":"J Clin Pathol"},{"key":"2415_CR18","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","volume":"39","author":"A Menzies-Gow","year":"2022","unstructured":"Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv Ther. 2022;39:2065\u201384.","journal-title":"Adv Ther"},{"key":"2415_CR19","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448\u201358.","journal-title":"N Engl J Med"},{"key":"2415_CR20","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstr\u00f6m V, Goldman M. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115\u201327.","journal-title":"Lancet"},{"key":"2415_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1183\/09031936.00011714","volume":"44","author":"W De Backer","year":"2014","unstructured":"De Backer W, Vos W, Van Holsbeke C, Vinchurkar S, Claes R, Hufkens A, Parizel PM, Bedert L, De Backer J. The effect of roflumilast in addition to LABA\/LAMA\/ICS treatment in COPD patients. Eur Respir J. 2014;44:527\u20139.","journal-title":"Eur Respir J"},{"key":"2415_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1067\/mai.2001.116576","volume":"108","author":"TK Hart","year":"2001","unstructured":"Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108:250\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"2415_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","volume":"167","author":"JC Kips","year":"2003","unstructured":"Kips JC, O\u2019Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwels RA. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma. Am J Respir Crit Care Med. 2003;167:1655\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2415_CR24","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128\u201341.","journal-title":"Lancet"},{"key":"2415_CR25","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall\u2019Acqua WW, Stephens GL, et al. MEDI-563, a humanized anti\u2013IL-5 receptor & #x3b1; mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344-1353.e1342.","journal-title":"J Allergy Clin Immunol"},{"key":"2415_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1517\/14712598.2012.642359","volume":"12","author":"A Ghazi","year":"2012","unstructured":"Ghazi A, Trikha A, Calhoun WJ. Benralizumab\u2013a humanized mAb to IL-5R\u03b1 with enhanced antibody-dependent cell-mediated cytotoxicity\u2013a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12:113\u20138.","journal-title":"Expert Opin Biol Ther"},{"key":"2415_CR27","first-page":"263","volume":"11","author":"W Vos","year":"2016","unstructured":"Vos W, Hajian B, De Backer J, Van Holsbeke C, Vinchurkar S, Claes R, Hufkens A, Parizel PM, Bedert L, De Backer W. Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS\/LABA\/LAMA. Int J Chron Obstruct Pulmon Dis. 2016;11:263\u201371.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2415_CR28","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1080\/17425247.2016.1200555","volume":"13","author":"B Hajian","year":"2016","unstructured":"Hajian B, De Backer J, Vos W, Aerts J, Cluckers J, De Backer W. Efficacy of inhaled medications in asthma and COPD related to disease severity. Expert Opin Drug Deliv. 2016;13:1719\u201327.","journal-title":"Expert Opin Drug Deliv"},{"key":"2415_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","volume":"7","author":"WW Busse","year":"2019","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7:46\u201359.","journal-title":"Lancet Respir Med"},{"key":"2415_CR30","first-page":"4381","volume":"9","author":"S Korn","year":"2021","unstructured":"Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, Gil EG. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol. 2021;9:4381\u201392.","journal-title":"J Allergy Clin Immunol"},{"key":"2415_CR31","volume-title":"Introduction to functional respiratory imaging","author":"J De Backer","year":"2016","unstructured":"De Backer J, De Backer W. Introduction to functional respiratory imaging. 1st ed. Kontich: Fluidda; 2016.","edition":"1"},{"key":"2415_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1089\/jamp.2013.1064","volume":"28","author":"J De Backer","year":"2014","unstructured":"De Backer J, Vos W, Vinchurkar S, Van Holsbeke C, Poli G, Claes R, Salgado R, De Backer W. The effects of extrafine beclometasone\/formoterol (BDP\/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging. J Aerosol Med Pulm Drug Deliv. 2014;28:88\u201399.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2415_CR33","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1148\/radiol.10100322","volume":"257","author":"JW De Backer","year":"2010","unstructured":"De Backer JW, Vos WG, Vinchurkar SC, Claes R, Drollmann A, Wulfrank D, Parizel PM, Germonpr\u00e9 P, De Backer W. Validation of computational fluid dynamics in CT-based airway models with SPECT\/CT. Radiology. 2010;257:854\u201362.","journal-title":"Radiology"},{"key":"2415_CR34","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2147\/COPD.S171707","volume":"13","author":"W De Backer","year":"2018","unstructured":"De Backer W, De Backer J, Vos W, Verlinden I, Van Holsbeke C, Clukers J, Hajian B, Siddiqui S, Jenkins M, Reisner C, Martin UJ. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate\/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2673\u201384.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2415_CR35","first-page":"OA2948","volume":"46","author":"W Vos","year":"2015","unstructured":"Vos W, Van Holsbeke C, Van Geffen W, Kerstjens H, Pistolesi M, Usmani O, Hajian B, Cahn A, De Backer J, De Backer W. Changes in functional respiratory imaging (FRI) endpoints correlate with changes in patient reported outcomes (PRO) after recovering from acute COPD exacerbation. Eur Respir J. 2015;46:OA2948.","journal-title":"Eur Respir J"},{"key":"2415_CR36","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2147\/COPD.S21917","volume":"6","author":"LA De Backer","year":"2011","unstructured":"De Backer LA, Vos WG, Salgado R, De Backer JW, Devolder A, Verhulst SL, Claes R, Germonpr\u00e9 PR, De Backer WA. Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:637\u201346.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2415_CR37","first-page":"PA2271","volume":"46","author":"W Vos","year":"2015","unstructured":"Vos W, Van Holsbeke C, Van Geffen W, Kerstjens H, Pistolesi M, Usmani O, Hajian B, Cahn A, De Backer J, De Backer W. Changes in FEV1 after recovery from COPD exacerbation are driven by heterogeneous regional changes in airway caliber and hyperinflation. Eur Respir J. 2015;46:PA2271.","journal-title":"Eur Respir J"},{"key":"2415_CR38","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2147\/COPD.S152463","volume":"13","author":"WH van Geffen","year":"2018","unstructured":"van Geffen WH, Hajian B, Vos W, De Backer J, Cahn A, Usmani OS, Van Holsbeke C, Pistolesi M, Kerstjens HA, De Backer W. Functional respiratory imaging: heterogeneity of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1783\u201392.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2415_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1586\/17476348.2016.1136216","volume":"10","author":"B Hajian","year":"2016","unstructured":"Hajian B, De Backer J, Vos W, Van Holsbeke C, Clukers J, De Backer W. Functional respiratory imaging (FRI) for optimizing therapy development and patient care. Expert Rev Respir Med. 2016;10:193\u2013206.","journal-title":"Expert Rev Respir Med"},{"key":"2415_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1183\/09041950.005s1693","volume":"6","author":"PH Quanjer","year":"1993","unstructured":"Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6:5\u201340.","journal-title":"Eur Respir J"},{"key":"2415_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.arbr.2018.04.003","volume":"54","author":"A Talaminos Barroso","year":"2018","unstructured":"Talaminos Barroso A, M\u00e1rquez Mart\u00edn E, Roa Romero LM, Ortega Ruiz F. Factors affecting lung function: a review of the literature. Archivos de Bronconeumolog\u00eda (English Edition). 2018;54:327\u201332.","journal-title":"Archivos de Bronconeumolog\u00eda (English Edition)"},{"key":"2415_CR42","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.acra.2020.07.019","volume":"27","author":"M Lins","year":"2020","unstructured":"Lins M, Vandevenne J, Thillai M, Lavon BR, Lanclus M, Bonte S, Godon R, Kendall I, De Backer J, De Backer W. Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT. Acad Radiol. 2020;27:1449\u201355.","journal-title":"Acad Radiol"},{"key":"2415_CR43","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1164\/rccm.201612-2438OC","volume":"196","author":"VJ Kelly","year":"2017","unstructured":"Kelly VJ, Hibbert KA, Kohli P, Kone M, Greenblatt EE, Venegas JG, Winkler T, Harris RS. Hypoxic pulmonary vasoconstriction does not explain all regional perfusion redistribution in asthma. Am J Respir Crit Care Med. 2017;196:834\u201344.","journal-title":"Am J Respir Crit Care Med"},{"key":"2415_CR44","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.chest.2019.05.019","volume":"156","author":"S Okauchi","year":"2019","unstructured":"Okauchi S, Yamada H, Satoh H. CT and functional MRI to evaluate airway mucus in severe asthma. Chest. 2019;156:808.","journal-title":"Chest"},{"key":"2415_CR45","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/ppul.24462","volume":"54","author":"A Bal\u00e1zs","year":"2019","unstructured":"Bal\u00e1zs A, Mall MA. Mucus obstruction and inflammation in early cystic fibrosis lung disease: emerging role of the IL-1 signaling pathway. Pediatr Pulmonol. 2019;54:S5\u201312.","journal-title":"Pediatr Pulmonol"},{"key":"2415_CR46","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1378\/chest.106.1.105","volume":"106","author":"KB Newman","year":"1994","unstructured":"Newman KB, Lynch DA, Newman LS, Ellegood D, Newell JD. Quantitative computed tomography detects air trapping due to asthma. Chest. 1994;106:105\u20139.","journal-title":"Chest"},{"key":"2415_CR47","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/17476348.2016.1192464","volume":"10","author":"J De Backer","year":"2016","unstructured":"De Backer J, Van Holsbeke C, Vos W, Vinchurkar S, Dorinsky P, Rebello J, Mangale M, Hajian B, De Backer W. Assessment of lung deposition and analysis of the effect of fluticasone\/salmeterol hydrofluoroalkane (HFA) pressurized metered dose inhaler (pMDI) in stable persistent asthma patients using functional respiratory imaging. Expert Rev Respir Med. 2016;10:927\u201333.","journal-title":"Expert Rev Respir Med"},{"key":"2415_CR48","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/COPD.S269001","volume":"15","author":"OS Usmani","year":"2020","unstructured":"Usmani OS, Scichilone N, Mignot B, Belmans D, Van Holsbeke C, De Backer J, De Maria R, Cuoghi E, Topole E, Georges G. Airway deposition of extrafine inhaled triple therapy in patients with COPD: a model approach based on functional respiratory imaging computer simulations. Int J Chron Obstruct Pulmon Dis. 2020;15:2433\u201340.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2415_CR49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J"},{"key":"2415_CR50","doi-asserted-by":"publisher","first-page":"AB47","DOI":"10.1016\/j.jaci.2020.12.201","volume":"147","author":"D Beuther","year":"2021","unstructured":"Beuther D, Murphy K, Zeiger R, Wise R, McCann W, Reibman J, George M, Gilbert I, Eudicone J, Ghandi H, et al. Baseline Asthma Impairment and Risk Questionnaire (AIRQ\u2122) control level is associated with future risk of exacerbations. J Allergy Clin Immunol. 2021;147:AB47.","journal-title":"J Allergy Clin Immunol"},{"key":"2415_CR51","first-page":"2263","volume":"8","author":"KR Murphy","year":"2020","unstructured":"Murphy KR, Chipps B, Beuther DA, Wise RA, McCann W, Gilbert I, Eudicone JM, Gandhi HN, Harding G, Coyne KS, et al. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): a composite control measure. J Allergy Clin Immunol. 2020;8:2263\u201374.","journal-title":"J Allergy Clin Immunol"},{"key":"2415_CR52","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1183\/09031936.05.00035205","volume":"26","author":"R Pellegrino","year":"2005","unstructured":"Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CPM, Gustafsson P, Hankinson J, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948\u201368.","journal-title":"Eur Respir J"},{"key":"2415_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12931-019-1017-y","volume":"20","author":"A Higham","year":"2019","unstructured":"Higham A, Quinn AM, Can\u00e7ado JED, Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. Respir Res. 2019;20:49\u201349.","journal-title":"Respir Res"},{"key":"2415_CR54","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/MCP.0000000000000018","volume":"20","author":"L Bjermer","year":"2014","unstructured":"Bjermer L. The role of small airway disease in asthma. Curr Opin Pulm Med. 2014;20:23\u201330.","journal-title":"Curr Opin Pulm Med"},{"key":"2415_CR55","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Critical Care Med. 2019;200:e70\u201388.","journal-title":"Am J Respir Critical Care Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02415-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02415-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02415-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T03:26:43Z","timestamp":1683084403000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02415-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2415"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02415-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"21 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice (ICH\/GCP) and applicable regulatory requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EG, DC, KR, VHS, FT: Are or were employees of AstraZeneca at the time of study design, may own stock or stock options. PM: Employee of FLUIDDA. WDB: Medical advisor for FLUIDDA. RP Jr: Has received research support from, and conducted advisory boards for, AstraZeneca, Sanofi, Regeneron, Genentech, and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}